Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 5/20 | 0.56 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.54 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.46 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2861407 | 0.89 | HDAC4 (0.51) | HDAC4OPRL1TACR1ERCC1ERCC4 | |
| SCHEMBL2863230 | 0.87 | HDAC4 (0.61) | HDAC4OPRL1ERCC1ERCC4LMNA | |
| SCHEMBL2858831 | 0.85 | HDAC4 (0.58) | HDAC4OPRL1ERCC1ERCC4LMNA | |
| SCHEMBL2865854 | 0.85 | TACR1 (0.64) | HDAC4OPRL1TACR1ERCC1ERCC4 | |
| SCHEMBL2870236 | 0.81 | TACR1 (0.51) | OPRL1TACR1ERCC1ERCC4MTOR | |
| SCHEMBL2860497 | 0.80 | TRPV1 (0.54) | OPRL1TACR1ERCC1ERCC4LMNA | |
| SCHEMBL5355699 | 0.80 | HDAC4 (0.49) | HDAC4OPRL1ALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL2859742 | 0.78 | SMN1; SMN2 (0.58) | HDAC4OPRL1TACR1ERCC1ERCC4 | |
| SCHEMBL14516605 | 0.75 | HDAC4 (0.52) | HDAC4OPRL1LMNAP2RX7ALDH1A1 | |
| SCHEMBL5347464 | 0.75 | HDAC4 (0.54) | HDAC4OPRL1ERCC1ERCC4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253328-A1 | Cycloalkyl inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050234106-A1 | Cycloalkyl inhibitors of potassium channel function | LLOYD JOHN | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234106-A1 | Cycloalkyl inhibitors of potassium channel function | KCNJ2, KCNN3, KCNQ5 | HDAC4 1442/4885OPRL1 1213/4885TACR1 2425/4885 |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNN3, KCNQ5 | HDAC4 1442/4885OPRL1 1213/4885TACR1 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.